Physicians' Academy for Cardiovascular Education

Icosapent Ethyl Resources

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME

A call to solve the controversy on omega-3FAs trials

5' education - May 17, 2021 - Prof. Eileen Handberg, PhD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

Introduction: The evolving role of triglycerides

10' education - Nov. 15, 2020 - Prof. Peter LIbby, MD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD - Online CME

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD - Online CME

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

Discussion: Novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides

10' education - Sep. 23, 2020

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Fish oil treatment reduces several plaque parameters after 9 months

3' education - Nov. 18, 2019 - Prof. Matthew Budoff - AHA 2019, Philadelphia

Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events

3' education - Mar. 19, 2019 - Deepak L. Bhatt, MD

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

NICE publishes final draft guidance on icosapent ethyl

News - June 13, 2022

The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides.

E-learning CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Watch the videos in this series and learn about icosapent ethyl in relation to CV risk and its potential mechanisms of action!

Icosapent ethyl decreases CVD risk after MI

Literature - May 16, 2022 - Gaba P et al. - J Am Coll Cardiol. 2022

In a subgroup analysis of REDUCE-IT, additional treatment with icosapent ethyl resulted in less ischemic events in statin-treated patients with prior MI.

Potential mechanisms of benefit of icosapent ethyl

10' education - May 3, 2022 - Prof. Chris Packard, PhD
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

Consistent benefit of icosapent ethyl across background statin agent and category

Literature - Jan. 12, 2022 - Singh N et al. - J Am Coll Cardiol. 2022

There was no difference of icosapent ethyl efficacy among statin agents and statin categories (lipophilic vs. lipophobic statins) in an exploratory analysis of the REDUCE-IT trial.

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD
Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19. patiënten met COVID-19.

AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.

Highly-purified EPA does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME
What is the role of icosapent ethyl in lowering residual CV risk? Prof. Steg answers this question by presenting observations from trials with EPA-based therapies.

What is the role of icosapent ethyl in lowering residual CV risk? Prof. Steg answers this question by presenting observations from trials with EPA-based therapies.

Triglyceride-rich lipoproteins and residual CV risk

Subtitling in English, German, Italian, Spanish, Chinese and French

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD
Is it relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.

Is it relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME
Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.

Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.